Welcome!

News Feed Item

Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation



 

 

 

 

LONDON, Jan. 22, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation


Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation

Summary

GBI Research has released its pharmaceuticals report, "Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation". The Alzheimer's Disease (AD) market is characterized by a lack of products with strong disease-modifying properties and a number of high-profile product failures in late stages of development over recent years. In addition, recent or impending patent expiries for all of the four currently marketed products and a late-stage pipeline with limited-to-moderate prospects are expected to impede growth over the next few years. In the medium-term future, the market is expected to be characterized by substantial generic competition and overall decline. However, the current development pipeline shows signs of meaningful innovation, although the vast majority of these products are currently in the early stages of development. Despite one of the highest drug attrition rates across the industry, a number of innovative and potentially disease-modifying therapeutics are likely to enter the market and translate recent insights into the etiology of AD combined with an earlier therapeutic intervention into better products, which will begin to transform the AD market towards the end of the decade.


Scope

- A brief introduction to AD etiology, pathogenesis, diagnosis, and treatment regimes
- Profiling of the marketed products in the AD market, including analysis of their safety, efficacy, treatment patterns, and strengths and weaknesses
- Comprehensive review of the pipeline for AD therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule type, and molecular target.
- Additional in-depth analysis of pipeline drug clinical trials, analyzed by phase, molecule type, trial size, trial duration and program failure rate, for each molecule type and mechanism of action
- Multi-scenario forecast data for the market to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across the key developed markets of the US, Japan, Germany, the UK, France, Italy and Spain
- Discussion of the drivers of and barriers to market growth
- Analysis of the licensing and co-development deals landscape

Reasons to buy

- Understand the different levels of AD therapies, from early-stage or mild AD to severe AD
- Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent
- Observe trends in terms of clinical trial duration and size among clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for AD therapeutics
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the AD therapeutics market
Table of Contents

1 Table of Contents 5
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Symptoms 8
2.2 Etiology 9
2.3 Pathophysiology 10
2.3.1 Amyloidosis 10
2.3.2 Tau Hyperphosphorylation 10
2.4 Comorbidities/Complications 11
2.5 Diagnosis 11
2.5.1 Physical Examination 12
2.5.2 Mini Mental State Exam 12
2.5.3 Alzheimer's Disease Assessment Scale-cognitive 14
2.5.4 Alzheimer's Disease Co-operative Study – Activities of Daily Living Inventory 15
2.5.5 Other Diagnostic Tests 15
2.5.6 Blood Tests 15
2.5.7 Imaging Tests 15
2.5.8 Lumbar Puncture 15
2.5.9 Disease Biomarkers 16
2.5.10 Biomarker Market 17
2.6 Prognosis 18
2.7 Treatment Options 18
2.7.1 Treatment Algorithm 19
2.7.2 Non-Pharmacological Treatments 19
3 Marketed Products 20
3.1 Namenda/Axura/Memary (memantine), Merz Pharma/Lundbeck/Forest Laboratories/Daiichi Sankyo 20
3.2 Aricept (donepezil), Eisai Inc. 21
3.3 Exelon (rivastigmine), Novartis AG 22
3.4 Razadyne (galantamine), Janssen Pharmaceuticals 22
3.5 Cognex (tacrine), Shiniogi Inc. 23
3.6 Unmet Need 24
4 Pipeline for Alzheimer's Disease Therapeutics 25
4.1 Overall Pipeline 25
4.2 Mechanisms of Action within the AD Pipeline 27
4.3 Clinical Trials 29
4.3.1 Clinical Trial Failure Rate 29
4.3.2 Clinical Trial Size 33
4.3.3 Clinical Trial Duration 35
4.4 Notable Pipeline Drugs 38
4.4.1 Solanezumab – Eli Lilly and Company 38
4.4.2 LMTX (Methylene Blue) – TauRX Therapeutics Ltd. 39
4.4.3 RG-1540 (gantenerumab) – Roche 39
4.4.4 AD-02 – AFFiRiS AG 40
4.4.5 MK-8931 – Merck & Co. 41
4.4.6 CAD-106 – Novartis AG 41
4.4.7 LuAE58054 – Lundbeck 42
4.4.8 Crenezumab (RG7412) – Genentech 42
4.5 Conclusion 42
5 Market Forecast to 2019 44
5.1 Geographical Markets 44
5.1.1 Key Developed Markets 44
5.1.2 US 47
5.1.3 Leading Five EU Countries (EU5) 49
5.1.4 Japan 53
5.2 Drivers and Barriers 55
5.2.1 Drivers 55
5.2.2 Barriers 56
6 Deals and Strategic Consolidations 58
6.1 Key Licensing Deals 58
6.1.1 Forest Laboratories Inc. Enters into Agreement with Adamas Pharmaceuticals Inc. 60
6.1.2 AC Immune SA Enters into an Agreement with Genentech Inc. 60
6.1.3 Cephalon Inc. Enters into Agreement with Mesoblast Limited 60
6.1.4 Acadia Pharmaceuticals Inc. Enters into Agreement with Biovail Laboratories International SRL 60
6.1.5 Astellas Pharma Inc. enters into Agreement with CoMentis Inc. 61
6.2 Key Co-development Deals 61
6.2.1 Evotec AG Enters into Agreement with F. Hoffman-La Roche Ltd. 63
6.2.2 Alectos Therapeutics Inc. Enters into Agreement with Merck & Co. Inc. 63
6.2.3 Targacept Inc. Expands Agreement with AstraZeneca PLC. 63
6.2.4 GlaxoSmithKline Enters into an Agreement with Epix Pharmaceuticals 64
7 Appendix 65
7.1 All Pipeline Drugs by Phase – Tables 65
7.2 Market forecast to 2019 - Tables 81
7.3 References 84
7.4 Abbreviations 87
7.5 Methodology 89
7.6 Secondary Research 89
7.7 Therapeutic Landscape 90
7.8 Contact Us 90
7.9 Disclaimer 90



List of Tables


Table 1: Alzheimer's Disease, Global, All Pipeline Products (Discovery) 65
Table 2: Alzheimer's Disease, Global, All Pipeline Products (Preclinical) 68
Table 3: Alzheimer's Disease, Global, All Pipeline Products (Phase I) 76
Table 4: Alzheimer's Disease, Global, All Pipeline Products (Phase II) 79
Table 5: Alzheimer's Disease, Global, All Pipeline Products (Phase III) 81
Table 6: Alzheimer's Disease, Global, Market Forecast, 2012–2019 81
Table 7: Alzheimer's Disease, US, Market Forecast, 2012–2019 81
Table 8: Alzheimer's Disease, UK, Market Forecast, 2012–2019 82
Table 9: Alzheimer's Disease, France, Market Forecast, 2012–2019 82
Table 10: Alzheimer's Disease, Germany, Market Forecast, 2012–2019 82
Table 11: Alzheimer's Disease, Italy, Market Forecast, 2012–2019 83
Table 12: Alzheimer's Disease, Spain, Market Forecast, 2012–2019 83
Table 13: Alzheimer's Disease, Japan, Market Forecast, 2012–2019 83



List of Figures



Figure 1: Mini-Mental State Exam 13
Figure 2: Alzheimer's Disease Assessment Scale Cognitive Subscale 14
Figure 3: Alzheimer's Disease, Overall Pipeline 26
Figure 4: Alzheimer's Disease, Mechanisms of Action in the Pipeline, 2006–2013 29
Figure 5: Alzheimer's Disease, Failure Rates of Clinical Trials, 2006–2013 30
Figure 6: Alzheimer's Disease, Failure Rates by Mechanism of Action, 2006–2013 31
Figure 7: Alzheimer's Disease, Reasons for Clinical Trial Failure, 2006–2013 32
Figure 8: Alzheimer's Disease, Clinical Trial Size by Phase, 2006–2013 33
Figure 9: Alzheimer's Disease, Clinical Trial Size by Molecule Type, 2006–2013 34
Figure 10: Alzheimer's Disease, Clinical Trial Duration by Phase, 2006–2013 35
Figure 11: Alzheimer's Disease, Clinical Trial Duration by Molecule Type, 2006–2013 36
Figure 12: Alzheimer's Disease, Global, 2012–2019 46
Figure 13: Alzheimer's Disease, US, 2012–2019 48
Figure 14: Alzheimer's Disease, EU5, Patient Number ('000) 2012–2019 50
Figure 15: Alzheimer's Disease, EU5, Annual Cost of Treatment ($), 2012–2019 51
Figure 16: Alzheimer's Disease, EU5, Market Size ($m), 2012–2019 52
Figure 17: Alzheimer's Disease, Japan, 2012–2019 54
Figure 18: Alzheimer's Disease, Global, Licensing Deals by Region and Year, 2012–2019 58
Figure 19: Alzheimer's Disease, Global, Licensing Deals by Phase and Molecule Type, 2012–2019 59
Figure 20: Alzheimer's Disease, Global, Co-development Deals by Region and Year, 2012–2019 61
Figure 21: Alzheimer's Disease, Global, Co-development Deals by Phase and Molecule Type, 2006–2013 62


Read the full report:
Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation
http://www.reportbuyer.com/pharma_healthcare/treatments/alzheimers_disea...

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that MangoApps will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. MangoApps provides modern company intranets and team collaboration software, allowing workers to stay connected and productive from anywhere in the world and from any device. For more information, please visit https://www.mangoapps.com/.
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, wh...
Enterprise networks are complex. Moreover, they were designed and deployed to meet a specific set of business requirements at a specific point in time. But, the adoption of cloud services, new business applications and intensifying security policies, among other factors, require IT organizations to continuously deploy configuration changes. Therefore, enterprises are looking for better ways to automate the management of their networks while still leveraging existing capabilities, optimizing perf...
The IoT is changing the way enterprises conduct business. In his session at @ThingsExpo, Eric Hoffman, Vice President at EastBanc Technologies, discuss how businesses can gain an edge over competitors by empowering consumers to take control through IoT. We'll cite examples such as a Washington, D.C.-based sports club that leveraged IoT and the cloud to develop a comprehensive booking system. He'll also highlight how IoT can revitalize and restore outdated business models, making them profitable...
SYS-CON Events announced today that ContentMX, the marketing technology and services company with a singular mission to increase engagement and drive more conversations for enterprise, channel and SMB technology marketers, has been named “Sponsor & Exhibitor Lounge Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York City, New York. “CloudExpo is a great opportunity to start a conversation with new prospects, but what happens after the...
Many banks and financial institutions are experimenting with containers in development environments, but when will they move into production? Containers are seen as the key to achieving the ultimate in information technology flexibility and agility. Containers work on both public and private clouds, and make it easy to build and deploy applications. The challenge for regulated industries is the cost and complexity of container security compliance. VM security compliance is already challenging, ...
The pace of innovation, vendor lock-in, production sustainability, cost-effectiveness, and managing risk… In his session at 18th Cloud Expo, Dan Choquette, Founder of RackN, will discuss how CIOs are challenged finding the balance of finding the right tools, technology and operational model that serves the business the best. He will discuss how clouds, open source software and infrastructure solutions have benefits but also drawbacks and how workload and operational portability between vendors...
The essence of data analysis involves setting up data pipelines that consist of several operations that are chained together – starting from data collection, data quality checks, data integration, data analysis and data visualization (including the setting up of interaction paths in that visualization). In our opinion, the challenges stem from the technology diversity at each stage of the data pipeline as well as the lack of process around the analysis.
As machines are increasingly connected to the internet, it’s becoming easier to discover the numerous ways Industrial IoT (IIoT) is helping to shape the business world. This is exactly why we have decided to take a closer look at this pervasive movement and to examine the desire to connect more things! Now if you need a refresher on IIoT and how it is changing the world, take a moment and listen to Greg Gorbach with ARC Advisory Group. Gorbach believes, "IIoT will significantly change the worl...
The 19th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit y...
Internet of @ThingsExpo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 19th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world and ThingsExpo New York Call for Papers is now open.
Designing IoT applications is complex, but deploying them in a scalable fashion is even more complex. A scalable, API first IaaS cloud is a good start, but in order to understand the various components specific to deploying IoT applications, one needs to understand the architecture of these applications and figure out how to scale these components independently. In his session at @ThingsExpo, Nara Rajagopalan is CEO of Accelerite, will discuss the fundamental architecture of IoT applications, ...
In his session at 18th Cloud Expo, Bruce Swann, Senior Product Marketing Manager at Adobe, will discuss how the Adobe Marketing Cloud can help marketers embrace opportunities for personalized, relevant and real-time customer engagement across offline (direct mail, point of sale, call center) and digital (email, website, SMS, mobile apps, social networks, connected objects). Bruce Swann has more than 15 years of experience working with digital marketing disciplines like web analytics, social med...
SYS-CON Events announced today that Enzu, a leading provider of cloud hosting solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Enzu’s mission is to be the leading provider of enterprise cloud solutions worldwide. Enzu enables online businesses to use its IT infrastructure to their competitive advantage. By offering a suite of proven hosting and management services, Enzu wants companies to foc...
Customer experience has become a competitive differentiator for companies, and it’s imperative that brands seamlessly connect the customer journey across all platforms. With the continued explosion of IoT, join us for a look at how to build a winning digital foundation in the connected era – today and in the future. In his session at @ThingsExpo, Chris Nguyen, Group Product Marketing Manager at Adobe, will discuss how to successfully leverage mobile, rapidly deploy content, capture real-time d...